Therapeutic potential of mesenchymal stem cells for refractory inflammatory and immune skin diseases

Abstract

Inflammatory and immunological skin diseases such as psoriasis, systemic sclerosis, dermatomyositis and atopic dermatitis, whose abnormal skin manifestations not only affected life quality but also caused social discrimination, have been wildly concerned. Complex variables such as hereditary predisposition, racial differences, age and gender can influence the prevalence and therapeutic options. The population of patients with unsatisfactory curative effects under current therapies is growing, it’s advisable to seek novel and advanced therapies that are less likely to cause systemic damage. Mesenchymal stem cells (MSCs) have been proven with therapeutic benefits in tissue regeneration, self-renewal and differentiation abilities when treating refractory skin disorders in preclinical and clinical studies. Here we highlighted the immune modulation and inflammation suppression of MSCs in skin diseases, summarized current studies, research progress and related clinical trials, hoping to strengthen the confidence of promising MSCs therapy in future clinical application.

Comparison of Cost and Potency of Human Mesenchymal Stromal Cell Conditioned Medium Derived from 2- and 3-Dimensional Cultures

“…In the past decade, mesenchymal stromal cell (MSC) therapy has been studied in several clinical trials for autoimmune conditions. Due to the immunomodulatory characteristics and anti-inflammatory capacity of MSCs [ 8 ], MSC therapy has emerged as a promising approach for autoimmune disorders [ 9 , 10 , 11 ] and chronic inflammation [ 12 , 13 ]. MSCs, initially isolated from bone marrow in 1987 [ 14 ], can also be obtained from various sources, such as adipose tissue, perinatal products (amniotic fluid, placenta, umbilical cord), dental pulp, and stromal vascular fraction, among others [ 15 , 16 ].…”